New Genomic Breast Cancer Test Now Available in the U.S.
新型基因組乳癌檢測現已在美國推出
更新於: 2026年6月8日 上午03:01
A significant advancement in cancer care has arrived in the United States.
癌症護理領域的一項重大進展已在美國實現。
As of June 8, 2026, Veracyte, Inc. has officially launched the Prosigna® Breast Risk of Recurrence (ROR) test.
自2026年6月8日起，Veracyte, Inc.
This genomic tool is designed for patients diagnosed with early-stage, hormone-receptor-positive (HR+) breast cancer, representing a major shift toward personalized medicine.
已正式推出Prosigna®乳癌復發風險（ROR）檢測。
By applying the PAM50 genomic classifier, the test generates a comprehensive risk score.
與著重於腫瘤物理特徵的傳統檢測不同，Prosigna利用先進的全轉錄體定序來分析腫瘤內部的特定基因。
This data helps oncologists determine the likelihood of cancer recurrence over a decade, guiding crucial decisions on whether a patient truly needs chemotherapy or can safely rely on endocrine therapy alone.
透過應用PAM50基因分類器，該檢測會產生一個全面的風險評分。
With over 225,000 such cases diagnosed annually in the U.S., this technology is set to improve quality of life by sparing many patients from unnecessary, harsh treatments.
此數據有助於腫瘤科醫師判斷未來十年間癌症復發的可能性，從而指導關鍵的決策，判斷患者是否確實需要化學治療，或者是否能單獨依賴內分泌治療。
Backed by recent clinical trials like the OPTIMA study, this launch marks a new era in tailoring cancer treatments to individual biological needs.
務必將此與遺傳檢測區分開來；Prosigna檢查的是現有的腫瘤生物學，而非遺傳突變。
